3349 Stock Overview
Engages in the retail sale of pharmaceuticals, cosmetics, daily necessities, food, etc. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 3349 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
COSMOS Pharmaceutical Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥7,610.00 |
| 52 Week High | JP¥8,178.00 |
| 52 Week Low | JP¥5,777.50 |
| Beta | 0.14 |
| 1 Month Change | 14.80% |
| 3 Month Change | -4.97% |
| 1 Year Change | -2.40% |
| 3 Year Change | 2.01% |
| 5 Year Change | 25.27% |
| Change since IPO | 2,325.50% |
Recent News & Updates
COSMOS Pharmaceutical Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Jan 17
Here's Why COSMOS Pharmaceutical (TSE:3349) Can Manage Its Debt Responsibly
Dec 25COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The Business
Nov 18Recent updates
COSMOS Pharmaceutical Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Jan 17Here's Why COSMOS Pharmaceutical (TSE:3349) Can Manage Its Debt Responsibly
Dec 25COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The Business
Nov 18We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt
Sep 26An Intrinsic Calculation For COSMOS Pharmaceutical Corporation (TSE:3349) Suggests It's 41% Undervalued
Aug 17COSMOS Pharmaceutical (TSE:3349) Will Want To Turn Around Its Return Trends
Aug 01Subdued Growth No Barrier To COSMOS Pharmaceutical Corporation's (TSE:3349) Price
Jun 28We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt
Jun 10COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Apr 17Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E Ratio
Mar 16Returns On Capital At COSMOS Pharmaceutical (TSE:3349) Paint A Concerning Picture
Feb 28Shareholder Returns
| 3349 | JP Consumer Retailing | JP Market | |
|---|---|---|---|
| 7D | 10.4% | 1.7% | -1.8% |
| 1Y | -2.4% | 4.9% | 6.3% |
Return vs Industry: 3349 underperformed the JP Consumer Retailing industry which returned 4.9% over the past year.
Return vs Market: 3349 underperformed the JP Market which returned 6.3% over the past year.
Price Volatility
| 3349 volatility | |
|---|---|
| 3349 Average Weekly Movement | 4.1% |
| Consumer Retailing Industry Average Movement | 2.8% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in JP Market | 7.3% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 3349 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 3349's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 5,512 | Hideaki Yokoyama | www.cosmospc.co.jp |
COSMOS Pharmaceutical Corporation engages in the retail sale of pharmaceuticals, cosmetics, daily necessities, food, etc. in Japan. It also sells its products through online stores. The company was incorporated in 1983 and is headquartered in Fukuoka City, Japan.
COSMOS Pharmaceutical Corporation Fundamentals Summary
| 3349 fundamental statistics | |
|---|---|
| Market cap | JP¥603.15b |
| Earnings (TTM) | JP¥27.30b |
| Revenue (TTM) | JP¥994.50b |
22.1x
P/E Ratio0.6x
P/S RatioIs 3349 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3349 income statement (TTM) | |
|---|---|
| Revenue | JP¥994.50b |
| Cost of Revenue | JP¥793.05b |
| Gross Profit | JP¥201.45b |
| Other Expenses | JP¥174.15b |
| Earnings | JP¥27.30b |
Last Reported Earnings
Nov 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 344.38 |
| Gross Margin | 20.26% |
| Net Profit Margin | 2.74% |
| Debt/Equity Ratio | 10.5% |
How did 3349 perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield9%
Payout RatioDoes 3349 pay a reliable dividends?
See 3349 dividend history and benchmarks| COSMOS Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Nov 28 2024 |
| Dividend Pay Date | Feb 12 2025 |
| Days until Ex dividend | 51 days |
| Days until Dividend pay date | 25 days |
Does 3349 pay a reliable dividends?
See 3349 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/17 21:42 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/11/30 |
| Annual Earnings | 2024/05/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
COSMOS Pharmaceutical Corporation is covered by 19 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Arashi Nishizawa | BofA Global Research |
| Mitsuru Takayanagi | Citigroup Inc |
| Jun Kawahara | Daiwa Securities Co. Ltd. |